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Negative ion fragmentationN-glycans were released from the SARS coronavirus (SARS-CoV) spike glycoprotein produced in Vero E6 cells
and their structures were determined by a combination of matrix-assisted laser desorption/ionization
(MALDI) mass spectrometry, negative ion electrospray collision-induced dissociation time-of-ﬂight mass
spectrometry and normal-phase high-performance liquid chromatography with exoglycosidase digestion.
Major glycans were high-mannose (Man5–9GlcNAc2), hybrid and bi-, tri- and tetra-antennary complex with
and without bisecting GlcNAc and core fucose. Complex glycans with fewer than the full complement of
galactose residues were present and sialylation was negligible. Treatment with the glucosidase inhibitor N-
butyl-deoxynojirimycin (NB-DNJ) inhibited N-glycan processing as evidenced by the appearance of glycans
of composition Glc3Man7–9GlcNAc2. However, some complex glycans remained suggesting the presence of an
α-endomannosidase. Our data in tissue culture indicate that inhibition of N-glycan processing may be
considered as a therapeutic strategy against SARS CoV infections.otensin converting enzyme 2;
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The aetiological agent of the severe acute respiratory syndrome
(SARS) is a coronavirus (SARS-CoV) which was responsible for
causing a worldwide pandemic of lower respiratory tract infection
between November 2002 and July 2003 (Drosten et al., 2003; Ksiazek
et al., 2003; Marra et al., 2003; Rota et al., 2003). During this time,
there were approximately 8100 probable SARS cases and approxi-
mately 800 recorded fatalities (http://www.wpro.who.int/sars/).
Rapid identiﬁcation of individuals presenting with the disease as well
as appropriate nursing techniques and quarantine proceduresallowed the outbreak to be controlled by July of 2003. There have
since been smaller outbreaks of the disease, but these have been
contained with minimal secondary transmission. In the clinic, SARS-
CoV infection presents as atypical pneumonia, with patients reporting
symptoms of high fever (N38 °C), dry cough, shortness of breath
(dyspnea) and/or more severe breathing difﬁculties, which may
occasionally require mechanical ventilation. The viral reservoirs are
presumed to be bats (Wang and Eaton, 2007; Wang et al., 2006) and
the palm civet cat has been implicated as a carrier of the virus, though
there may also be other asymptomatic animal carriers (Shi and Hu,
2008).
Of the several proteins found in the SARS coronavirus (Tan et al.,
2006; Ying et al., 2004), the large SARS-CoV spike glycoprotein (S)
(Tripet et al., 2004) located on the virion surface is involved in both
target cell attachment and fusion processes (Yang et al., 2004). As
with several coronaviruses, the spike glycoprotein can be proteolyt-
ically cleaved into two non-covalently associated glycoproteins: the
virion-associated S1 (666 amino acid residues) containing the
receptor attachment site and the transmembrane-anchored S2 (583
residues) responsible for fusion activity (Bergeron et al., 2005; Follis
et al., 2006; Li et al., 2005).
The SARS-CoV S glycoprotein is a 1255-amino acid precursor
polypeptide as deduced from the published genome sequence and has
258 G. Ritchie et al. / Virology 399 (2010) 257–26923 potential N-linked glycosylation sites (Eickmann et al., 2003;
Marra et al., 2003; Rota et al., 2003; Xiao et al., 2003). Previous studies
have demonstrated that several of these sites are occupied and
possess both complex-type and high-mannose type N-glycans
(Krokhin et al., 2003; Song et al., 2004; Ying et al., 2004). However,
full glycan analysis has not yet been performed.
SARS-CoV uses the angiotensin converting enzyme 2 (ACE2) as
the primary receptor (Chen and Subbarao, 2007; Li et al., 2003;
Moore et al., 2004; Wang et al., 2004) suggesting that oligoman-
nose-containing N-glycans on the SARS-CoV S glycoprotein surface
may be involved in mediating virus attachment to cells expressing
this cell surface lectin. The C-type lectins DC-SIGN and L-SIGN (DC/
L-SIGN) can enhance viral entry (Marzi et al., 2004; Yang et al.,
2004). Site-directed mutagenesis analyses have identiﬁed seven
glycosylation sites on the S protein critical for DC/L-SIGN-mediated
virus entry. They include asparagine residues 109, 118, 119, 158,
227, 589, and 699, which are distinct from residues of the ACE2-
binding domain (amino acids 318–510) (Han et al., 2007). Recently,
L-SIGN (DC-SIGNR) has been shown to act as an entry receptor for
SARS-CoV infection (Jeffers et al., 2004), and its expression in lung
alveolar and liver cells correlates with the disease pathogenesis
observed in these organs in many SARS patients.
Given that oligomannose N-glycans may be involved in viral
attachment to cells it is of interest to study the effects of modiﬁcations
to the N-glycan proﬁle with the object of possibly identifying
therapeutic strategies. This report describes the ﬁrst complete N-
glycosylation analysis of SARS-CoV S glycoprotein produced in Vero
E6 cells, a cell line derived from African green monkeys, and
demonstrates the inhibitory effect of the α-glucosidase inhibitor N-
butyl-deoxynojirimycin (NB-DNJ) on virus replication in this cell line.
Results and discussion
Characterization of SARS-CoV spike protein
Viral proteins from puriﬁed viral particles were separated on 9%
SDS-PAGE gels and stained with Coomassie blue (Fig. 1). The proteins
S, M and N were detected but the gel was not dense enough to detect
the smaller (7 kDa) E protein. Western blotting using the SARS-CoV S
glycoprotein antibody (Imgenex) conﬁrmed the identity and molec-
ular weight (180 kDa) of the S protein which was consistent with
earlier reports (Krokhin et al., 2003; Song et al., 2004; Xiao et al.,
2003) and indicated the presence of the fully modiﬁed glycoprotein.
There was no apparent difference in molecular weight between the
glycoproteins produced with and without NB-DNJ.Fig. 1. SDS-PAGE and western blotting analysis of puriﬁed SARS-CoV (strain Tor2)
preparation. Left panel: 9% SDS-PAGE analysis of SARS-CoV virion preparation.
S=SARS-CoV spike glycoprotein, N=SARS-CoV nucleoprotein, M=SARS-CoV matrix
protein. Molecular weight markers are shown on the left. Right panel: Western blotting
analysis of SARS-Co V virion preparation using an anti-SARS-CoV S antibody (Imgenex).
U, untreated preparation; D, drug(NB-DNJ) treated preparation; M, mock infected
preparation.Identiﬁcation of N-glycans
The spike glycoprotein-containing band was cut from the gel for N-
glycan analysis by in-gel PNGase F digestion followed by HPLC (as 2AB
derivatives), exoglycosidasedigestion,MALDI-TOF andnanoelectrospray
MS/MS as described below. The HPLC trace of the SARS-CoV glycans
obtained without NB-DNJ treatment is shown in Fig. 2a. Traces obtained
before andafter digestionwithArthrobacter ureafaciens sialidase (Fig. 2b)
were virtually identical showing negligible incorporation of sialic acid in
these glycans. Previous work (Feldmann et al., 1994) has also shown a
lack of sialylatedN-glycans in Marburg virus grown in Vero E6 cells. The
positive ion MALDI (Fig. 3) and negative ion nanoelectrospray spectra
were similar to each other and to the HPLC trace although more glycans
were resolved by mass spectrometry. Table 1 lists the identiﬁed glycans
and their percentage of the total glycan pool asmeasured byMALDI-TOF
MS and Table 2 lists the percentage of various compound glycan types.
Because a few of the glycanswith different structures had the samemass
and were, thus, not separated by mass spectrometry, the ﬁgures should
be taken as approximate. Nevertheless, they reﬂect the composition of
the mixture reasonably accurately.
The glycans were identiﬁed by exoglycosidase digestion with
monitoring by HPLC and by negative ionMS/MS of their [M+H2PO4]−
ions (Harvey, 2005a) using electrospray sample introduction (Harvey,
2005b,c; Harvey et al., 2008b). The HPLC traces obtained after ABS and
bovine testis β-galactosidase (BTG) treatment (Fig. 2c) conﬁrmed
attachment of galactose at the non-reducing termini of the glycan
antenna. Further incubation with hexosaminidase (Fig. 2d) reduced
the proﬁle to Man3GlcNAc2, Man3GlcNAc2Fuc1 and a series of
unaffected high-mannose glycans. A few compounds were present
at concentrations that were too weak to permit acquisition of
informative MS/MS spectra. However, their structures could be
deduced from the structures of related compounds, e.g., complex
glycans with different numbers of galactose residues. Such com-
pounds are identiﬁed in Table 1. Ion nomenclature in the following
discussion follows that introduced by Domon and Costello (1988) as
modiﬁed by Harvey et al. (2004) by the use of the subscript “R” to
specify cleavages adjacent to the reducing-terminal GlcNAc residueFig. 2. (a) NP-HPLC analysis of SARS-CoV S N-glycans. (b) HPLC analysis of SARS-CoV N-
glycans following digestion with Arthrobacter ureafaciens sialidase (ABS, EC 3.2.1.18),
(c) HPLC analysis following digestion with a mixture of ABS and bovine testis β-
galactosidase (BTG, EC 3.2.1.23) and (d) HPLC analysis following incubation with a
mixture of ABS, BTG and Streptococcus pneumoniae hexosaminidase (GUH, EC 3.2.1.30).
The broken lines connecting the peaks in the various traces show movement of the
peaks following digestion. Symbols used for the structural formulae: ■=GlcNAc,
○=mannose, ◊=galactose, =fucose. The angle of the lines connecting the symbols
shows the linkage with full and broken lines specifying β- and α-linkages, respectively.
Further details are given in the paper by Harvey et al. (2009).
Fig. 3. Positive ion MALDI-TOF mass spectrum ([M+Na]+ions) of the N-linked glycans obtained from the SARS-CoV spike protein. Peaks are identiﬁed in Table 1 and the key to the
structural symbols is in the legend to Fig. 2 with the addition of □=glucose. Glycan types are coloured: blue=high mannose, orange=hybrid, purple=monoantennary,
red=biantennary, green=triantennary, pink=tetra-antennary.
259G. Ritchie et al. / Virology 399 (2010) 257–269and “R-1” to specify cleavages adjacent to the penultimate GlcNAc in
order to avoid confusion by the subscript number changing as a
function of antenna length.
High-mannose glycans
High-mannose glycans containing from four to nine mannose
residues were present in the glycan mixture (Fig. 3). Incubation with
Aspergillus saitoi a-mannosidase (data not shown) reduced the larger
compounds toMan5GlcNAc2 (compound 3, Table 1) conﬁrming theα-
mannose linkages. The negative ion MS/MS spectra of the high-
mannose glycans Man5–9GlcNAc2 (phosphate adducts) are shown in
Fig. 4. The cross-ring 2,4AR and 2,4AR-1 fragments together with the BR-1
ion at the high-mass end of the spectra deﬁne the 1→4-linked
chitobiose core (Harvey, 2005b; Harvey et al., 2008b) and the single
C1 fragment atm/z 179 conﬁrmed hexose (mannose) as the only non-
reducing end residue. The ions towards the centre of the spectrum
were mainly derived from the 6-antenna and allowed the distribution
of the mannose residues between the two antennae to be determined.
Predominant among these ions were the D-ion (formal loss of the 3-
antenna from the CR-1 ion), the [D-18]− ion and the O,3AR-2 cross-ring
cleavage fragment (core mannose residue) (Harvey, 2005b). Thus,
Man5GlcNAc2 (3) produced a spectrum with these ions at m/z 647,
629 and 575, respectively. Further conﬁrmation of the substitution
pattern was provided by the C2 ion at m/z 503 (three mannose
residues). In the spectrum of Man6GlcNAc2 (7, Fig. 4b) the D, [D-18]−
and O,3AR-2 ions were in the same position as in the spectrum of
Man5GlcNAc2 showing that the sixth mannose was attached to the 3-
antenna. These three diagnostic ions all shifted by 162 mass units to
higher mass in the spectrum of Man7GlcNAc2 (12, Fig. 4c) showing
that the seventhmannose was attached to the 6-antenna and the high
abundance of the ion at m/z 485 was consistent with its location on
the 6-branch of this antenna. This ion, termed D′, is thought to be
equivalent to ion D as the result of the same substitution pattern of thebranched mannose of the 6-antenna to that at the mannose of the
core. This same pattern of D, [D-18]−, O,3AR-2 and D′ ions was present
in the spectrum of Man8GlcNAc2 (19, Fig. 4d) conﬁrming attachment
of the 8th mannose to the 3-antenna and indicating that this
compound had the classical d1,d3-substitution pattern. Finally, in
the spectrum of Man9GlcNAc2 (25, Fig. 4e), the three 6-antenna-
derived diagnostic ions shifted upwards by another 162 mass units to
m/z 971, 953 and 899 as the result of the extra mannose residue in the
6-antenna. The presence of a second set of the D, [D-18]−, O,3AR-2 ions
at m/z 647, 629 and 575 in the spectrum of Man7GlcNAc2 (12)
indicated the presence of a second isomer with three mannose
residues in the 3-antenna. A fragmentation spectrum was not
obtained for Man4GlcNAc2 (1).
Hybrid glycans
Hybrid glycans (numbers 9, 13, 14 and 20, Table 1) were detected
in the mass spectra but were not apparent in the HPLC trace of the
total glycans. However, they became visible by HPLC following
incubation with Jack bean α-mannosidase which removed all of the
mannose residues from the 6-antenna to leave the chitobiose core and
3-antenna which consisted of GlcNAc and Gal-GlcNAc (data not
shown). Fig. 5 shows the negative ion MS/MS spectra of the hybrid
glycans 9 (Fig. 5a) and 14 (Fig. 5b). The pattern of mannose
substitution on the 6-antenna was determined by the masses of the
D, [D-18]−, O,3AR-2, D′ and [D′-18]− ions in the negative ion MS/MS
spectra as described above. The spectrum of the glycan corresponding
to Hex5GlcNAc3 (9, Fig. 5a) showed the presence of two compounds as
evidenced by the appearance of two sets of D and [D-18]− ions (m/z
647/629 and 485/467) indicating three and two mannose residues
respectively in the 6-antenna. The linkage of the mannose residue in
the compounds with two mannose residues in the 6-antenna was not
determined. Location of the fucose at position 6 of the terminal
GlcNAc residue, when present, was determined by the masses of the
Table 1
N-linked glycans with the masse of their [M+Na]+ and [M+H2PO4]− ions.
No.a GUb m/z Composition Structuree
MALDI ([M+Na]+)c Electrospray
([M+H2PO4]−)d
Hex HexNAc dHex
Found Calc. Found Calc.
1 — 1095.7 1096.0 — 1169.3 4 2 0
f
2 — 1136.9 1137.0 — 1210.4 3 3 0 f
3 6.17 1258.1 1258.1 1331.4 1331.4 5 2 0
4 — 1283.8 1283.2 1356.6 1356.4 3 3 1
5 — 1299.4 1299.2 — 1372.4 4 3 0 f
6 — 1339.9 1340.2 1413.5 1413.5 3 4 0
7 7.05 1420.2 1420.2 1493.5 1493.5 6 2 0
8 6.40 1444.7 1445.3 1518.5 1518.5 4 3 1
9 — 1461.4 1461.3 1534.5 1534.5 5 3 0
10 5.89 1486.4 1486.4 1559.5 1559.5 3 4 1
11 — 1502.0 1502.4 1575.5 1575.5 4 4 0 f
12 7.94 1582.4 1582.4 1655.5 1655.5 7 2 0
13 — 1607.7 1607.4 1680.5 1680.5 5 3 1
14 — 1623.9 1623.4 1696.5 1696.5 6 3 0
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Table 1 (continued)
No.a GUb m/z Composition Structuree
MALDI ([M+Na]+)c Electrospray
([M+H2PO4]−)d
Hex HexNAc dHex
Found Calc. Found Calc.
15 6.63
6.81
1648.3 1648.5 1721.6 1721.6 4 4 1
16 7.13 1664.4 1664.5 1737.6 1737.6 5 4 0
17 6.17
6.27
1689.9 1689.6 1762.6 1762.6 3 5 1
18 6.50 1705.3 1705.5 1778.5 1778.6 4 5 0
19 8.80 1744.7 1744.5 1817.6 1817.6 8 2 0
20 — 1769.9 1769.6 1842.6 1842.6 6 3 1
21 7.54 1810.8 1810.6 1883.6 1883.6 5 4 1
22 — 1851.9 1851.7 1924.6 1924.6 4 5 1
23 7.24 1867.7 1867.7 1940.6 1940.6 5 5 0
24 6.86 1893.0 1892.7 1965.6 1965.7 3 6 1
25 9.48 1907.5 1906.7 1979.6 1979.6 9 2 0
(continued on next page)
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Table 1 (continued)
No.a GUb m/z Composition Structuree
MALDI ([M+Na]+)c Electrospray
([M+H2PO4]−)d
Hex HexNAc dHex
Found Calc. Found Calc.
26 7.65 2014.0 2013.8 2086.7 2086.7 5 5 1
27 8.32 2029.8 2029.8 2102.7 2102.7 6 5 0
28 8.02 2055.0 2054.9 2127.7 2127.7 4 6 1
29 8.67 2176.2 2176.0 2248.7 2248.8 6 5 1
30 — 2217.3 2217.0 2289.7 2289.8 5 6 1
31 — 2232.8 2233.0 — 2305.8 6 6 0
32 9.26 2379.6 2379.2 2451.8 2451.8 6 6 1
33 — 2395.4 2395.2 — 2467.8 7 6 0
34 9.95 2541.5 2541.3 2613.8 2613.9 7 6 1
35 — 2744.1 2744.5 — 2817.0 7 7 1 f
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Table 1 (continued)
No.a GUb m/z Composition Structuree
MALDI ([M+Na]+)c Electrospray
([M+H2PO4]−)d
Hex HexNAc dHex
Found Calc. Found Calc.
36g 10.27 — — — — 10 2 0 g
37g 11.16 — — — — 11 2 0 g
38g 11.80 — — — — 12 2 0 g
a Peak numbers as in the MALDI-TOF spectrum (Fig. 3).
b Glucose unit.
c Average mass.
d Monoisotopic mass.
e Symbols used for the structural formulae: ■=GlcNAc, ○=mannose, ◊=galactose, =fucose, □=glucose. The angle of the lines connecting the symbols shows the linkage
with full and broken lines specifying β- and α-linkages, respectively.
g In the presence of NB-DNJ only.
f Not conﬁrmed by fragmentation.
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2005c; Harvey et al., 2008b) all of which were formed by loss of the
fucose residue as the result of its attachment to the eliminated neutral
fragment. Structures are shown in Table 1. No antenna-substituted
fucose was detected in these or in the spectra of the complex glycans.
The composition of the 3-antenna was speciﬁed by the mass of an E-
type cross-ring fragment ion (substituents plus 101 mass units from
the mannose residue (Harvey, 2005c; Harvey et al., 2008b)). These
ions were of low abundance but were present at m/z 304 and 466 in
the spectrum shown in Fig. 5a and atm/z 466 in Fig. 5b conﬁrming the
presence of GlcNAc and Gal-GlcNAc antennae respectively. The 3-
antenna composition was further deﬁned by an O,3A cross-ring
cleavage ion formed by fragmentation of the mannose residue and
which appeared at 59 mass units above the mass of the substituents
linked to the mannose (m/z 262 for a GlcNAc-containing antenna and
m/z 424 for Gal-GlcNAc, see Fig. 5).
Complex glycans
Representative spectra are shown in Fig. 6. Bi-, tri- and tetra-
antennary glycans were found, with andwithout core fucose andwith
and without a bisecting GlcNAc residue. Exoglycosidase digestion
with ABS, BTG and GUH (Fig. 2) showed that the antennae consisted of
galactose and GlcNAc only. Their negative ion MS/MS spectra were
identical to those from reference standards. The branching structureof the triantennary glycan (29, Fig. 6c) was revealed by themass of the
E3 ion (m/z 831, the subscript “3” indicates its origin from the 3-
antenna) (Harvey, 2005c; Harvey et al., 2008a). This ion was also
present in the spectrum of the tetra-antennary glycan (34, Fig. 6d)
but, whereas the D and [D-18]− ions from the 6-antenna in the
spectrum of the triantennary glycan were at the same m/z values
(688 and 670 respectively) as in the spectrum of the biantennary
glycan (Fig. 6a), they moved tom/z 1053 and 1035 in the spectrum of
the tetra-antennary glycan reﬂecting the presence of the additional
Gal-GlcNAcmoiety in the 6-antenna. An additional [D-36]− ion atm/z
1017 was also characteristic of this branched structure on the 6-
antenna. The fucose substitution pattern on the core GlcNAc residue
was deﬁned by the masses of the 2,4AR, 2,4AR-1 and BR-1 ions as
described above. The occurrence of a bisecting GlcNAc residue was
determined by the presence of an abundant [D-221]− ion (e.g., m/z
670 in Fig. 6b), equivalent in mass to the [M-18]− ion from the
corresponding compound that did not contain a bisecting GlcNAc
residue, as described earlier (Harvey et al., 2008b).
These basic complex structures were accompanied by relatively
large amounts of analogues with fewer numbers of galactose residues
(Table 1), conﬁrmed by incubations with bovine testis β-galactosi-
dase. Four representative spectra are shown in Fig. 7. All illustrated
compounds contain a fucose residue attached to the core GlcNAc as
shown by the masses of the 2,4AR, 2,4AR-1 and BR-1 ions as above. The
spectrum of the biantennary glycan lacking both galactose residues
Table 2
Percentages of various groups of N-glycan in SARS spike glycoprotein.
Glycan type % Total
High-mannose — 30
Hybrid — 28
Complex Total 42
Biantennary 19
Triantennary 12
Tetraantennary 11
Truncated hybrid and complex (no galactose) — 21
264 G. Ritchie et al. / Virology 399 (2010) 257–269(10, Fig. 7a) contained D and [D-18]− ions at m/z 526 and 508,
respectively, consistent with the absence of galactose in the 6-
antenna. The C1 ion was at m/z 220 showing GlcNAc at the non-
reducing terminus. Addition of one galactose residue (Fig. 7b)
produced a mixed spectrum of glycans with the galactose attached
to either antenna (15) as shown by the two pairs of D and [D-18]−
ions atm/z 526/508 (major isomer) and atm/z 688/670. Two C1 ions
at m/z 179 and 220 conﬁrmed both hexose (galactose) and GlcNAc,
respectively, at the non-reducing terminus. The 1,3A3 ion at m/z 424
was consistent with the presence of a Gal-GlcNAc-containing antenna.
Most of the other spectra from the glycans containing low
galactose were of mixtures. They were interpreted by postulation of
the expected ions, based on the structures of the identiﬁed fully
galactosylated compounds and ﬁnding the relevant diagnostic ions in
the spectra. Thus, the spectrum of the compounds having the
composition Man3GlcNAc5Fuc1 (17, Fig. 7c) would be expected to
contain contributions from the bisected biantennary glycan and the
triantennary glycan, both lacking galactose. The spectrum contained a
prominent ion at m/z 507 at the expected mass of the E ion from the
triantennary glycan lacking galactose and D and [D-18]− ions at m/z
526/508 from the 6-antenna. The enhanced relative abundance of the
ion at m/z 508 suggested the presence of a small amount of theFig. 4. Negative ion MS/MS spectra of the [M+H2PO4]− ions from the high-mannose glycans
Ions are labelled according to the scheme introduced by Domon and Costello (1988).bisected biantennary glycan, this ion corresponding to [D-221]−. The
two compounds (24) producing the spectrum in Fig. 7d were the
degalactosylated tetra-antennary glycan and the bisected triantenn-
ary compound. The former compound produced the characteristic D,
[D-18]− and [D-36]− triplet at m/z 729, 711 and 693 from the 6-
antenna and the E ion at m/z 507. The other, minor compound was
characterized by the [D-221]− ion at m/z 508. The ion corresponding
to the antenna mass plus 59 mass units (C2H3O2 from the attached
mannose) also deﬁned the antenna composition (the speciﬁc cross-
ring cleavage producing these A-type ions varied with the linkage
position of the antenna).
Effect of NB-DNJ treatment
Effect of NB-DNJ against SARS-CoV infection
Following infection with SARS-CoV (strain Tor2, MOI=10-4) and
incubation with the iminosugar inhibitor NB-DNJ, the integrity of the
Vero E6 cell monolayer was monitored daily by light microscopy. At
NB-DNJ concentrations of 100 μg/mL and above, the cell monolayer
remained intact and showed no signs of virally-induced cytopathic
effects (CPE). However, no signiﬁcant toxicity was seen at this drug
concentration as shown by the XTT assay (data not shown).
Effect of NB-DNJ treatment on N-glycan proﬁles
Fig. 8b shows the NP-HPLC proﬁle of the N-glycans from the spike
protein that was obtained in the presence of NB-DNJ at 100 μg/mL, the
concentration that protected the cells against CPE. The glycansof higher
molecular weight than were observed in the sample without NB-DNJ
were identiﬁed by HPLC and exoglycosidase digestion (A. ureafaciens
sialidase, bovine testis β-galactosidase S. pneumonia N-acetyl-hexosa-
minidase, Jack bean α-mannosidase and bovine kidney α-fucosidase)
asGlc3Man7GlcNAc2, Glc3Man8GlcNAc2 andGlc3Man9GlcNAc2 showing
that NB-DNJ at the concentration used (100 μg/mL) was able toMan5–9GlcNAc2. Symbols for the structural diagrams are deﬁned in the legend to Fig. 2.
Fig. 5. Negative ion MS/MS spectra of the [M+H2PO4]− ions from the hybrid glycans 9 and 14. Symbols for the structural diagrams are deﬁned in the legend to Fig. 2.
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removal of the terminal glucose residues from the 3-antenna. α-
Mannosidase was, however, still able to remove the outer mannose
residues from the 6-antenna to give the observed compounds.Fig. 6. Negative ion MS/MS spectra of the [M+H2PO4]− ions from (a) the fucosylated bianten
triantennary glycan 29 and (d) the fucosylated tetra-antennary glycan 34. Symbols for theAlthough processing of the 3-antenna was blocked, complex glycans
were still found in the proﬁle. The most likely reason would be the
presence of an endo-mannosidase that was able to split off Glc3Man
from the 3-antenna. Such an enzyme has been reported from ratsnary glycan 21, (b) the bisected, fucosylated biantennary glycan 26, (c) the fucosylated
structural diagrams are deﬁned in the legend to Fig. 2.
Fig. 7. Negative ion MS/MS spectra of the [M+H2PO4]− ions from (a) the fucosylated biantennary glycan lacking galactose (10), (b) a mixture of the fucosylated biantennary glycan
with one galactose residue on either antenna (15), (c) a mixture of the fucosylated triantennary glycan and the bisected biantennary glycan lacking galactose (17) and (d) a mixture
of the fucosylated tetra-antennary glycan and the bisected triantennary glycan lacking galactose (24). Symbols for the structural diagrams are deﬁned in the legend to Fig. 2.
Fig. 8. (a) NP-HPLC analysis of SARS-CoV N-glycans obtained without (a) and with (b)
100 μg/mL NB-DNJ. Peaks are identiﬁed in Table 1. The three glycans with residual
glucose residues are highlighted.
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but there appears to be no information on its possible occurrence in the
African green monkey. However, the high abundance of the peak
labelled as 29 in Fig. 8b is accounted for by the isomer of Man8GlcNAc2
that has lost a mannose residue from the 3-antenna (same GU value as
the fucosylated triantennary glycan) supporting this proposal.
Although the postulated endomannosidase activity permits ex-
tensive N-glycan processing with the production of complex glycans
and a nearly normal proﬁle in the presence of NB-DNJ, the drug
prevents formation of the mono-glucosylated N-glycans that are
necessary for binding to the chaperones calnexin and calreticulin that
are essential for correct protein folding. Viral surface glycoproteins are
dependent on such an interaction for correct folding (Vigerust and
Shepherd, 2007). Thus, α-glucosidase inhibition will prevent this
interaction and potentially lead to regional or global glycoprotein
misfolding. Therefore, the observation that the SARS-CoV S glycopro-
tein can undergo extensiveN-glycan processing to complex structures
in the presence of NB-DNJ does not necessarily correlate with proper
glycoprotein folding. Unfortunately, the necessary conformationally
sensitive anti-SARS-CoV S antibodies for testing this conclusion were
not available at the time this study was performed. Improper folding
induced by NB-DNJ could explain the protective effect of the drug
towards viral infection but the ability to retain complex N-glycan
processing could contribute to the drug's low cytotoxicity.
Conclusions
This study is the ﬁrst to describe fully the range of N-glycans
present on the SARS-CoV spike glycoprotein. They consisted mainly ofhigh-mannose (Man5–9GlcNAc2, about 30% of the total glycans),
hybrid (28%) and bi-, tri- and tetra-antennary complex glycans (42%)
with and without both bisecting GlcNAc and core fucose. Complex
glycans with fewer than the full complement of galactose residues
were present in relatively high abundance with 49% of the complex
glycans carrying no galactose. Sialylation was negligible. No evidence
was found for glycans with N-acetyllactosamine extensions or with
fucose attached to an antenna. The relatively high abundance of
267G. Ritchie et al. / Virology 399 (2010) 257–269complex glycans lacking one or more of the normal galactose residues
might indicate the involvement of the lectin, LSECtin in viral binding,
as recently found for Ebola virus (Powlesland et al., 2008).
Treatment with the glucosidase inhibitor NB-DNJ inhibited N-
glycan processing as evidenced by the appearance in the proﬁles of
glycans of composition Glc3Man7–9GlcNAc2. However, some complex
glycans still appeared in the glycan proﬁle, suggesting the presence of
an α-endomannosidase that was able to hydrolyse the Glc3-Man3
chain of the 3-antenna allowing attachment of GlcNAc in the ﬁrst step
towards complex glycan biosynthesis. Protection of cells against the
cytopathic effects of the virus, possibly as the result of the inhibition of
glycan processing, suggests a possible use of glucosidase inhibitors to
treat SARS-CoV infections.
Materials and methods
Materials
Methanol was obtained from BDH Ltd. (Poole, UK). Ammonium
phosphate and 2,5-dihydroxybenzoic acid (DHB) were from Aldrich
Chemical Co. Ltd. (Poole); water was distilled before use in a quartz
apparatus. NB-DNJ was a gift from Monsanto Searle (St Louis, USA).
Preparation of SARS-CoV
All work with infectious SARS-CoV was performed in the high
biocontainment laboratory of the National Microbiology Laboratory
(NML) of the Public Health Agency of Canada (PHAC). Vero E6 cells
(ATCC CRL-1586, kidney epithelial cells derived from African green
monkeys (Cercopithecus aethiops)) were cultured in Dulbecco's modi-
ﬁed Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS)
and subsequently infected with the Tor2 strain of the SARS-CoV (Marra
et al., 2003) at an MOI of 10−4 with and without the presence of
different concentrations (0, 100, 500 and 1000mg/mL) ofNB-DNJ. After
1 h of virus adsorption, cells were washed 3 times and DMEM supple-
mentedwith 2% FBS (with andwithoutNB-DNJ)was added. Forty-eight
hours post-infection, the cell supernatant was harvested and cells were
cleared by low-speed centrifugation. Virus particles were pelleted
through a 20% sucrose cushion at 20,000 rpm for 2 h, washed with PBS
and resuspended and inactivated in 1×sample loading buffer with 1.5%
SDS. Infectivity was further inactivated by heating the specimens at
100 °C for 15 min prior to removal from high biocontainment.
Assay for cellular toxicity
Vero E6 cells were cultured in 96-well plates in DMEM
supplemented with 10% FBS. At 80% conﬂuency the medium was
removed and replaced with DMEM/2% FBS containing various
concentrations (10–1000 μg/mL) of NB-DNJ, 5 wells per each
concentration. Drug cytotoxicity was assessed on days 1, 2 and 3
post-treatment using the XTT metabolic assay (Roche, Laval, Canada)
according to the manufacturer's directions.
SDS-PAGE analysis of SARS-CoV preparation
The SARS-CoV preparation was analysed by 9% polyacrylamide gel
electrophoresis (SDS-PAGE) followed by Coomassie blue staining. The
stained protein band corresponding to the SARS-CoV S glycoprotein
was cut from the gel for enzymatic digestion with peptide N-
glycosidase F (PNGase F, Roche Diagnostics Ltd., Basel, Switzerland)
and subsequent N-glycan analysis (see below).
Western blotting analysis of the SARS-CoV S glycoprotein
To conﬁrm that the band selected for N-glycan analysis was that
corresponding to the SARS-CoV S glycoprotein, an anti-SARS-CoV Santibody was used in a western blotting protocol. Brieﬂy, the SARS-CoV
preparation was subjected to SDS-PAGE on a 9% gel and the proteins
were transferred to PVDF membranes using the semi-dry transfer
technique. The membranes were blocked in 5% milk solution in 1×
phosphate-buffered saline (PBS) overnight then incubated with a
mouse anti-SARS IgG1 (clone 16F1071, Imgenex, CA, USA) diluted
1:1000 in 3% milk solution at room temperature for at least 1 h. The
membranes were washed three times in PBS–0.05% Tween-20 before 1
h incubation at roomtemperaturewith ahorseradishperoxidase (HRP)-
conjugated goat anti-mouse secondary antibody (Sigma Chemicals)
diluted 1:1000 in 3% milk solution. The membranes were washed three
times in PBS–0.05% Tween-20, then once with PBS. The SARS-CoV
glycoprotein band was detected by developing the membranes using
the ECL Western blotting detection kit (Amersham Biosciences, Little
Chalfont, UK) according to themanufacturers instructions and followed
by exposure to X-ray ﬁlm (CL-X Posure ﬁlm, Pierce).
N-glycan release using peptide N-glycosidase F
The procedure essentially followed that described by Küster et al.
(1997). The glycoproteins were separated by SDS-PAGEwith a BioRad
Mini-Protean II apparatus with 80×80×0.75 mm plates and a 9%
resolving gel. Developed gelswere stainedwith Coomassie Blue R-250.
The SARS-CoV S glycoprotein gel bands were excised from the gel and
cut into pieces about 1mm2,washedwith 300 μL 20mMNaHCO3 (BDH
Limited, Poole, UK) and soaked in the buffer for 30min. This procedure
was repeated twice; on the third wash, 45 mM dithiothreitol (20 μL)
was added and incubated for 30min at 60 °C to reduce disulﬁde bonds.
Iodoacetamide (100 mM; 20 μL) was added and the solution was
incubated for 30 min in the dark. Then a 1:1 (v/v) solution (300 μL) of
aqueous acetonitrile:20 mM NaHCO3, pH 7.0, was added and
incubated for 60 min followed by vacuum drying. PNGase F (EC
3.2.2.18, 30mL, 100 U/mL; Roche Diagnostics Ltd.) and NaHCO3 buffer
(enough to cover the gel, 70–100 μL) was added to the dried gel pieces
which were incubated at 37 °C for 12–16 h (overnight). The
supernatant was retained and the gel was washed twice with water
(200 μL), and then with acetonitrile (200 μL, Riedel de Häen
Laboratory, Seelze, Germany); thewasheswere collected and desalted
by incubation with 50 μL H+-activated AG-50, then centrifuged. The
supernatant was ﬁltered through 0.45 μm Millipore LH hydrophilic
PTFE syringe-tip ﬁlter then vacuum dried in preparation for direct
mass spectrometric analysis or 2-aminobenzamide (2AB) labelling
followed by HPLC analysis. Samples for mass spectrometric analysis
were further cleaned by drop dialysis with a Naﬁon 117 membrane
(Börnsen et al., 1995).
Glycan derivatisation with 2-aminobenzamide
Glycans were labelled with 2AB by reductive amination (Bigge et
al., 1995) using a 2AB labelling kit fromGlyko (now part of Prozyme at
Hayward, CA, USA). The 2AB labelling solution was prepared
according to the manufacturer's instructions and stored at −20 °C.
Five microliters of this solution was added to the dried sugars and
incubated at 65 °C for 2 h. Residual 2AB reagent was removed by
ascending paper chromatography on 3MM chromatography paper
(Millipore, Watford, UK) in 100% acetonitrile. After 2 h, the sample
was viewed under a UV light and the spot corresponding to the
labelled sugars was cut from the paper and the sugars were eluted
using four sequential aliquots of water (0.5 mL) into a nitric acid-
washed glass tube. The eluted N-glycans were vacuum dried and then
redissolved in water (200 μL).
Glycan sequencing using exoglycosidase digestion
One to two picomoles of 2AB-labelled N-glycans were vacuum
dried and incubated at 37 °C for 10 h in 50 mM sodium citrate
268 G. Ritchie et al. / Virology 399 (2010) 257–269buffer (pH 5.2) with exoglycosidases (Glyko) as follows: Arthro-
bacter ureafaciens sialidase (ABS, EC 3.2.1.18), a mixture of ABS and
bovine testis β-galactosidase (BTG, EC 3.2.1.23), and a mixture of
ABS, BTG and Streptococcus pneumoniae N-acetyl-hexosaminidase
(GUH, EC 3.2.1.30) at the manufacturer's recommended concentra-
tions. In a second experiment, glycans were incubated with Jack
bean mannosidase (JBM, EC 3.2.1.24) 10 μL, 50 U/mL and Asper-
gillus saitoi α1-2-mannosidase (ASM), 2 μL, 1 mU/mL. The enzymes
were removed after exoglycosidase digestions using washed
(200 μL water, centrifugation at 7000 rpm for 10 min) nitrocellu-
lose 0.45 μm microspin ﬁlters (Radleys, Saffron Walden, UK). The
sample (10 μL) was added to the ﬁlter and centrifuged at
13,000 rpm for 3 min. The digestion tube was washed with water
(20 μL) which was transferred to the ﬁlter and centrifuged at
13,000 rpm for 3 min. The ﬁlter was rinsed with water (100 μL)
and centrifuged at 13,000 rpm for a further 3 min. The collected
solution was vacuum dried and then redissolved in water (20 μL)
for analysis by HPLC.
Normal-phase HPLC analysis
Acetonitrile (80 μL) was added to 10% of the sample (20 μL) and
95 μL was examined on a normal-phase (NP)-HPLC system (Waters
Alliance 2690, Waters Corporation, Milford, MA, USA) ﬁtted with a
GlycoSep N column (Oxford GlycoSciences, Abingdon, UK) with a run
time of 180 min (Guile et al., 1996). The N-linked sugars eluted from
the column with a retention time of between 40 and 120 min.
Comparison with a dextran ladder allowed assignment of glucose unit
(GU) values to each peak, which facilitated identiﬁcation of the
glycans present in the released pool.
Matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS)
Positive ion MALDI-TOF mass spectra were obtained with a
Waters-MS Technologies TofSpec 2E reﬂectron TOF mass spectrom-
eter (Waters Ltd, Manchester). The pulse and acceleration voltages
were 3 and 20 kV, respectively. Data acquisition and processing were
performed with MassLynx software version 3.3. Samples were
prepared by mixing an aqueous solution of the sample (0.5 μL) with
a saturated solution of DHB in acetonitrile (0.3 μL) on the stainless
steel MALDI target and allowing the mixture to dry under ambient
conditions. The dried sample spot was then re-dissolved in ethanol
(0.2 μL) and again allowed to dry.
Electrospray mass spectrometry
Electrospray mass spectrometry was performed with a Waters
quadrupole-time-of-ﬂight (Q-TOF) Ultima Global instrument in
negative ion mode. Samples in 1:1 (v:v) methanol:water were
infused through Proxeon nanospray capillaries (Proxeon Biosystems,
Odense, Denmark). The ion source conditions were as follows:
temperature, 120 °C; nitrogen ﬂow, 50 L/h; infusion needle
potential, 1.2 kV; cone voltage, 100 V; RF-1 voltage, 150 V. Spectra
(2 s scans) were acquired with a digitization rate of 4 GHz and
accumulated until a satisfactory signal:noise ratio had been
obtained. The major ions were [M+H2PO4]−, the phosphate
apparently arising from residual phosphate in the original sample,
as observed previously from all glycan samples released as above.
For MS/MS data acquisition, the parent ion was selected at low
resolution (about 5 m/z mass window) to allow transmission of
isotope peaks and fragmented with argon at a pressure (recorded
on the instrument's pressure gauge) of 0.5 mBar. The voltage on the
collision cell was adjusted with mass and charge to give an even
distribution of fragment ions across the mass scale. Typical values
were 80–120 V. Other voltages were as recommended by themanufacturer. Instrument control, data acquisition and processing
were performed with MassLynx software version 4.0. Displayed
spectra have been smoother using the Savitzky Golay algorithm
(5×2) and abundant background ions at m/z 195, 291 and 344
have been removed for clarity.
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